Amaranta Craig, MD
Gynecologic Oncology · Albuquerque, NMNPI 1881004281
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (32.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Intuitive Surgical at 54.5% of the total. Reporting peaked in 2024 at $4,217 and has fallen 97.1% since, to $124 in 2025.
Across 61 payments — averaging $138.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AstraZeneca$2K
- Eisai Inc.$1K
- AbbVie$124
- Genmab U.S., Inc.$107
- GSK$100
- plus $478 from 14 others
What the payments were for
- Grants$2,71132%
- Travel & lodging$2,54030%
- Food & beverage$1,18514%
- Education$2,00024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $4,598 |
| AstraZeneca | 10 | $1,953 |
| Eisai Inc. | 4 | $1,075 |
| AbbVie | 1 | $124 |
| Genmab U.S., Inc. | 2 | $107 |
| GSK | 4 | $100 |
| Novartis | 3 | $78 |
| Johnson & Johnson | 3 | $66 |
| Merck | 3 | $56 |
| Bayer | 3 | $51 |
| Sanofi | 1 | $40 |
| Seagen Inc. | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $24 |
| Incyte Corporation | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,434
- DAVINCI XI$2,000
- Elahere$124
How this compares
Too few gynecologic oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine OdtOlanzapine | 13 | $298 |
| Ondansetron Hcl | 17 | $238 |
| Prochlorperazine Maleate | 13 | $223 |
| Duloxetine Hcl | 11 | $175 |
| Oxycodone Hcl | 34 | $134 |
| Ibuprofen | 25 | $122 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Albuquerque
- Luis Padilla PazAlbuquerque$99K
- Stephanie RiederAlbuquerque$76K
- Ketura WisnerAlbuquerque$23K
- Karen FinkelsteinAlbuquerque$16K
- Carolyn MullerAlbuquerque$6K
- Joel WebbAlbuquerque$5K
- Leo TwiggsAlbuquerque$3K
- Sarah AdamsAlbuquerque$521
- Katijane DexterAlbuquerque$510
- Teresa RutledgeAlbuquerque$195
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.